此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

SAMBA EU Femoropopliteal Trial

2010年6月7日 更新者:NovoStent Corporation
The primary objective of this study is to evaluate the safety and performance of the SAMBA Stent and Delivery System in the treatment of femoropopliteal lesions.

研究概览

研究类型

介入性

注册 (实际的)

39

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Bad Krozingen、德国、D 79189
        • Herz Zentrum Bad Krozingen
      • Leipzig、德国、D-04289
        • Herz-Zentrum Leipzig

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

21年 及以上 (成人、年长者)

接受健康志愿者

有资格学习的性别

全部

描述

Inclusion Criteria:

Screening

  1. Patient must be ≥ 21 years of age with life expectancy > 1 year.
  2. Symptomatic leg ischemia requiring treatment of the superficial femoral and/or popliteal artery (Rutherford category 2-4; claudication, rest pain).
  3. Patient must be a suitable candidate for PTA and stenting.
  4. Patient is willing and able to return to the site of the investigation at the specified study intervals and undergo follow-up requirements.
  5. The patient or legal representative has provided written informed consent using a form that is reviewed and approved by the EC for the Clinical Site.

Pre-Intervention

  1. Target lesion has ≥ 50% stenosis as demonstrated angiographically.
  2. Lesion length ≤ 15 cm.
  3. Reference vessel diameter of 5 to 6 mm.
  4. Patient has at least 1 vessel run-off prior to treatment.

Exclusion Criteria:

Screening

  1. The subject is pregnant or will become pregnant during the study or has any other condition that would preclude having x-rays. (Pre-menopausal women must have a negative pregnancy test within 7 days of the procedure.)
  2. Patients who have experienced a cardiovascular accident (CVA) or a myocardial infarction (MI) within 3 months prior to the procedure.
  3. Subject has had or plans to have a surgical or interventional procedure within 30 days before or after the implantation procedure of the SAMBA Stent.
  4. Existing hemorrhagic disease or coagulation problems or inability to take dual anti-platelet therapy.
  5. Contrast allergy that cannot be corrected with medication (e.g. steroids, etc.).
  6. Subject has other medical, social, or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment and the procedures and evaluations pre- and post-treatment.
  7. Patient is currently participating in another investigational drug or device study.

Pre-Intervention

  1. Uncorrectable severe aorto-iliac occlusive disease or severe common femoral artery stenosis preventing access or limiting inflow (e.g., stenosis greater than 50%).
  2. Uncorrectable occlusive disease limiting outflow (e.g., stenosis greater than 50%)
  3. Patients with previous surgery in the target vessel or stent that will be closer than 2 cm to either edge of SAMBA Stent(s).
  4. Lack of 1 cm of healthy vessel proximal to proximal target
  5. Lack of popliteal reconstitution (at least 2 cm of normal distal popliteal).
  6. Inability to cross the lesion with a guidewire.
  7. More than 1 lesion in the same limb requiring treatment that will not be covered by continuous stenting.
  8. Unsuccessful balloon pre-dilation (i.e., the residual stenosis is greater than 30%).

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Stent placement
Stenting of atherosclerotic lesions post pre-dilatation of lesion(s)
其他名称:
  • SAMBA Stent and Delivery System

研究衡量的是什么?

主要结果指标

结果测量
大体时间
The primary safety endpoint is defined as freedom from all cause death, unplanned index limb amputation, and target lesion revascularization.
大体时间:through 30 days
through 30 days
The primary efficacy endpoint is defined as stent patency via Color Duplex Ultrasound (Peak Velocity Ratio ≤ 2.5).
大体时间:3 months
3 months

次要结果测量

结果测量
大体时间
Clinically-Driven Target Lesion Revascularization (i.e., with documented preintervention evidence of at least 50% diameter stenosis (quantitative angiographic ≥ 50% or PSVR > 2.5).
大体时间:12 months
12 months
Change in Rutherford Classification compared to pre-implant.
大体时间:12 months
12 months
Stent Patency via Color Duplex Ultrasound (Peak Systolic Velocity Ratio ≤ 2.5).
大体时间:12 months
12 months
Stent Fractures.
大体时间:12 months
12 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Dierk Scheinert, MD、Herz-Zentrum Leipzig

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2009年4月1日

初级完成 (预期的)

2010年9月1日

研究完成 (预期的)

2010年9月1日

研究注册日期

首次提交

2010年6月4日

首先提交符合 QC 标准的

2010年6月7日

首次发布 (估计)

2010年6月8日

研究记录更新

最后更新发布 (估计)

2010年6月8日

上次提交的符合 QC 标准的更新

2010年6月7日

最后验证

2010年6月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

Stenting of atherosclerotic lesion(s)的临床试验

3
订阅